Press enter to begin your search

Open Orphan - Preferred Partner Agreement

ORPH
Tue, 12 Nov 2019, 07:05 GMT

Open Orphan, a European-focussed, rare and orphan drug consulting services platform company, is pleased to announce the signing of a preferred partner agreement between Open Orphan and Ipsen Group. This partnership is the first of many steps to make the Company profitable and deliver a re-rating of the business to be in line with the wider sector.

Cathal Friel
CEO
ORPH
5dc99abe34a3cf1389e844e9
SHOW MORE
FROM THIS COMPANY
Open Orphan - Preferred Partner Agreement
ORPH Tue, 12 Nov 2019, 07:05 GMT

Open Orphan was founded in 2017, with the goal of becoming Europe’s leading rare disease and orphan drug-focused pharma services company by a management team with extensive industry and financial expertise.

Industry: Health Care

Contact: +353 (01) 6440007
Dublin 2, Ireland
https://www.openorphan.com

Open Orphan, a European-focussed, rare and orphan drug consulting services platform company, is pleased to announce the signing of a preferred partner agreement between Open Orphan and Ipsen Group. This partnership is the first of many steps to make the Company profitable and deliver a re-rating of the business to be in line with the wider sector.

Cathal Friel
CEO
POWERED BY